Sara Mariotto, MD, PhD - Beyond Myasthenia Gravis: What Are We Learning About FcRn Inhibitors in Other Rare Neuroimmunological Disorders?

Visit https://www.peervoice.com/EEZ860 to view the entire programme with slides. After completing “Sara Mariotto, MD, PhD - Beyond Myasthenia Gravis: What Are We Learning About FcRn Inhibitors in Other Rare Neuroimmunological Disorders?”, participants will be able to: Explain the biological function of the neonatal Fc receptor (FcRn) and its role in regulating immunoglobulin G (IgG) homeostasis; Explain the role of pathogenic IgG in the pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and the scientific rationale for FcRn inhibition as a therapeutic strategy; and Evaluate the latest clinical research and ongoing trials assessing FcRn inhibitors in MOGAD and/or CIDP.

Listen